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Single-base resolution mapping of 5-hydroxymethylcytosine 
modifications in hippocampus of Alzheimer’s disease subjects
Elizabeth M. Ellisona, Melissa A. Bradley-Whitmanb, and Mark A. Lovella,b,*
aDepartment of Chemistry, University of Kentucky, Lexington, KY
bSanders-Brown Center on Aging, University of Kentucky, Lexington, KY
Abstract
Epigenetic modifications to cytosine have been shown to regulate transcription in cancer, 
embryonic development, and recently neurodegeneration. While cytosine methylation studies are 
now common in neurodegenerative research, hydroxymethylation studies are rare, particularly 
genome-wide mapping studies. As an initial study to analyze 5-hydroxymethylcytosine (5-hmC) in 
the Alzheimer’s disease (AD) genome, reduced representation hydroxymethylation profiling 
(RRHP) was used to analyze more than 2 million sites of possible modification in hippocampal 
DNA of sporadic AD and normal control subjects. Genes with differentially hydroxymethylated 
regions were filtered based on previously published microarray data for altered gene expression in 
hippocampal DNA of AD subjects. Our data show significant pathways for altered levels of 5- 
hmC in the hippocampus of AD subjects compared to age-matched normal controls involved in 
signaling, energy metabolism, cell function, gene expression, protein degradation, and cell 
structure and stabilization. Overall, our data suggest a possible role for the dysregulation of 
epigenetic modifications to cytosine in late stage AD.
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Introduction
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, and 
diagnosis of AD is projected to exceed 13 million patients by 2050 (Fargo 2014). AD, the 
most common type of neurodegeneration in the elderly, is characterized by memory loss, 
decreased cognition, and specific pathologic markers including amyloid plaques, composed 
of the amyloid beta (Aβ) peptide; and neurofibrillary tangles (NFT) composed of 
hyperphosphorylated microtubule associated protein tau (Walsh & Selkoe 2004). A genetic 
component has been linked to familial AD, e.g. mutations in amyloid precursor protein 
(APP), presenilin 1 (PS1) and presenilin 2 (PS2) (Selkoe 1997), however, in sporadic/late-
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onset AD (LOAD), a clear mechanism of dysfunction and neurodegeneration remains 
elusive. Several susceptibility genes, most commonly APOE, have been identified in large 
genome-wide association studies, but exactly how these genes influence AD etiology is not 
well understood (reviewed by (Karch & Goate 2015).
Non-genetic factors, such as oxidative damage and epigenetic modifications, could 
potentially contribute to the complexity of AD dysfunction. Although oxidative damage 
plays a role in AD (Zhao & Zhao 2013), the effects of epigenetic modification remain 
unclear. With the discovery of several oxidative derivatives of 5-methylcytosine (5-mC), the 
most common epigenetic mark to the genome, generated by the ten-eleven translocase 
(TET) family of enzymes, the field of epigenetics as it relates to neurodegeneration has 
advanced steadily.
5-mC is oxidized by TET to generate 5-hydroxymethylcytosine (5-hmC), which is further 
oxidized by TET to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) (Tahiliani 
et al. 2009). These derivatives are thought to play a role in regulating gene transcription, 
although their exact function remains unclear. Methylation of cytosine can deregulate 
transcription (Nabel et al. 2012), but hydroxymethylation modifications show varied effects 
on gene expression. While 5-hmC modifications of introns and exons are generally thought 
to provide an increase in gene expression, the presence of this epigenetic mark within 
promoters has shown conflicting results (Nabel et al. 2012). Boundary locations of 
modification can alter gene expression as well as individual marks of 5-hmC at key genomic 
locations (transcription start and stop sites, enhancer regions, etc.) that could potentially be 
more important than overall distribution of modifications within genomic regions (Wen et al. 
2014, Wen & Tang 2014). Further research is needed to elucidate how locations of 5-hmC 
modifications affect gene expression.
Whether epigenetic marks are altered in AD compared to normal aging is controversial, as 
global levels of 5-mC and 5-hmC have been reported with seemingly conflicting results, 
possibly attributed to variations in quantitative/semi-quantitative analytical techniques 
(Bradley-Whitman & Lovell 2013, Chouliaras et al. 2013, Condliffe et al. 2014, Coppieters 
et al. 2014, Lashley et al. 2014, Mastroeni 2016). Recently, our lab analyzed DNA of brain 
tissue specimens from cognitively normal and demented subjects using gas chromatography/
mass spectrometry, and showed altered global levels of 5-mC and 5-hmC, indicating 
epigenetic modifications to cytosine may play a role in early stages of AD, including 
preclinical AD and mild cognitive impairment, in brain regions susceptible to plaque and 
tangle formation (Ellison et al. 2017).
While measurement of bulk levels of epigenetic modification provides valuable insight into 
regions of the brain susceptible to epigenetic changes throughout AD, determination of loci- 
specific levels of modification throughout the genome could enhance our understanding of 
how these epigenetic markers affect specific gene targets, as well as gene transcription 
changes and essential biological pathways and processes deregulated in AD. Genome-wide 
methylation mapping using bisulfite conversion has been used to analyze differentially 
methylated regions throughout the genome, providing gene targets relevant to AD 
progression that may be epigenetically regulated (Bakulski et al. 2012) (De Jager et al. 2014) 
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(Lunnon et al. 2014). Although bisulfite conversion has been the technique of choice to 
study genome-wide methylation of cytosine in the past, this technique is unable to 
distinguish between 5-mC and 5- hmC (Huang et al. 2010). Recently, three sequencing 
techniques, oxBS-seq (oxidative bisulfite sequencing), TAB-seq (TET-assisted bisulfite 
sequencing), and reduced representation hydroxymethylation profiling (RRHP), have 
advanced the field by specifically quantifying 5- hmC throughout the genome (Booth et al. 
2012) (Petterson et al. 2014) (Schuler & Miller 2012). RRHP is suggested to be the most 
sensitive technique, utilizing specific restriction endonuclease enzymes to detect 5-hmC 
modifications throughout the genome without the use of harsh chemical labeling techniques 
(Petterson et al. 2014).
As a follow up to our global study of altered 5-mC and 5-hmC levels throughout the 
progression of AD (Ellison et al. 2017), our lab sought to analyze loci-specific levels of 5-
hmC modifications in DNA isolated from the hippocampus/parahippocampal gyrus (HPG) 
of late onset AD subjects compared to NC. In this study, we hypothesize that biological 
pathways with altered hydroxymethylomes relevant to AD will be determined, providing 
future gene targets to study 5-hmC modification and the potential role these modifications 
play in AD. Using an in- house RRHP procedure by Zymo Research Corporation (CA, US), 
millions of sites of potential hydroxymethylation were identified. To find meaningful 
statistical relationships between counts of 5-hmC between the subject groups, a negative 
binomial distribution analysis was used. Biological relevance to pathways with altered 5-
hmC modifications were analyzed using the Cytoscape plugin app, Reactome Functional 
Interaction (FI) network. Pathways related to signaling, energy metabolism, gene expression, 
protein degradation, cell function, and cell structure and stabilization were significantly 
enriched in genes with altered 5-hmC levels according to our analysis, giving insight into the 
potential role epigenetic modifications to cytosine play in Alzheimer’s disease and 
neurodegeneration.
Materials and methods
AD diagnosis
Tissue specimens were obtained from short postmortem interval (PMI) autopsies of three 
LOAD and two age-matched normal control (NC) subjects through the Neuropathology 
Core of the University of Kentucky Alzheimer’s Disease Center (UK-ADC), in accordance 
with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and 
IRB approved protocols. All subjects in the UK-ADC are followed longitudinally, where 
annual neuropsychological testing and biannual physical examinations are completed 
(Schmitt et al. 2000). All AD subjects met the criteria for the clinical diagnosis of AD based 
on the AD and Consortium to Establish a Registry for Alzheimer’s disease (CERAD) and 
the National Institute of Aging-Reagan Institute (NIA-RI) neuropathology criteria 
(McKhann et al. 1984, Mirra et al. 1991, Hyman & Trojanowski 1997). Postmortem scores 
of AD-related pathologic markers using Braak stage scoring and diffuse and neuritic plaques 
were determined as described previously (Braak & Braak 1995, Nelson et al. 2007). 
Cognitive function was determined based on the Mini Mental State Examination (MMSE) 
(Folstein et al. 1975) for AD and NC subjects. At autopsy, specimens of hippocampus/
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parahippocampal gyrus (HPG) were flash frozen in liquid nitrogen and stored at −80°C until 
processed for analysis.
DNA isolation
DNA isolation was performed as previously described (Mecocci et al. 1993, Wang et al. 
2006, Bradley-Whitman & Lovell 2013). Briefly, 250 mg of frozen tissue was digested using 
a 5 mg proteinase-K/10 mL digestion buffer (0.5% sodium dodecyl sulfate, 0.05 M Tris, 0.1 
M EDTA, 0.1 M CaCl2, pH 7.5) solution and centrifuged at 7,000 × g for 5 min. Nuclear 
DNA (nDNA) was extracted using 25:24:1 phenol: chloroform: isoamyl alcohol and was 
precipitated overnight at −20°C in 80 μL of 5 M NaCl and 1.5 mL cold ethanol solution. 
After three washes in 60% ethanol, the nDNA pellet was dried and resuspended in ddH2O. 
Concentration and purity were measured by UV absorption analysis using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific, NY, US).
5-hmC whole genome profiling
To analyze sites of 5-hmC modification at single base resolution, 1 μg of nDNA was 
submitted to Zymo Research Corporation (ZRC) (CA, US) for analysis by reduced 
representation hydroxymethylation profiling (RRHP), which utilizes specific restriction 
endonuclease enzymes to analyze CCGG sequences throughout the genome (Petterson et al. 
2014). As described previously by Petterson et al. (Petterson et al. 2014), the specific 
restriction endonuclease MspI cuts between the CC bases in the CCGG sequence. If the 
internal cytosine (CCGG) is modified as 5-hmC, glucosylation of this site protects it from 
MspI cleavage and the epigenetic marker can be evaluated at each CCGG site. RRHP library 
construction and sequencing, as well as alignment to the human genome and count reads 
were performed by ZRC, resulting in more than 2 million sites of possible 5-hmC 
modification across the genomes of three LOAD and two NC subjects. Data files were 
downloaded from ZRC.
Data analysis
Data BAM files from ZRC were converted to BED format using a bedtools PERL script 
bamtobed (Quinlan & Hall 2010), freely available from the Comprehensive Perl Archive 
Network (cpan.org). BED files were analyzed using an exact negative binomial test (Anders 
& Huber 2010) which utilizes a sliding window approach in diffReps v1.55.4 (Shen et al. 
2013), a free PERL script initially designed for analysis of CHIP-Seq count data. In 
diffReps, the window size was set to 200 base pairs (bp) with a slide of 20 bp. Normalization 
of read counts within 200 bp windows was performed in diffReps, where raw read counts 
were linearly scaled by the geometric mean of all the reads in the specified window for each 
sample. Only windows that pass an initial uncorrected p value (p < 1e−04) cutoff were 
retained. Windows that passed this cutoff were adjusted for multiple comparisons using the 
Benjamini-Hochberg false discovery rate (FDR) (Benjamini & Hochberg 1995). To annotate 
windows to the hg19 human genome, a free PYTHON script regionanalysis.py, a now 
standalone script initially written for diffReps, was used. All scripts were run using 
command line calling in Terminal v2.6.1 (Apple, Inc., Cupertino, CA, USA).
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Due to the small sample size of subjects in this analysis, a conservative cutoff was used in 
which only windows with an adjusted FDR p value (p ≤ 1e−04) were retained for 
downstream analysis. Sites that aligned to promoter or genebody locations were filtered 
based on a published microarray of differentially expressed genes in the hippocampus of AD 
subjects (Blalock et al. 2004). This particular hippocampal AD microarray was chosen 
because the cohort came from the UK-ADC, where enrollment criteria and PMI were the 
same as the subjects in the current study. This list of 329 overlapping genes was generated 
for pathway enrichment analysis.
Functional Interaction Network Analysis
Using the Reactome FI (RFI) plugin app available through Cytoscape3.0, a gene network of 
functionally related genes was created. With the use of linker genes provided by RFI, 
322/329 genes with transcription and hydroxymethylation changes in the hippocampus of 
AD subjects compared to NC were used to create the network. The gene network was then 
clustered into six modules using spectral partition clustering (Newman 2006) and 
enrichment scores for module pathways were determined, excluding linker genes to prevent 
bias and only give pathways relevant to the 322 target genes. Statistical significance for 
pathway enrichment was determined in RFI using a binomial test (Huang da et al. 2009), 
while multiple comparisons were corrected for using a permutation test to give FDR p 
values (Vandin et al. 2011, Vandin et al. 2012). Only pathways with adjusted FDR (p < 0.05) 
were retained.
Statistical Analysis
To determine significant differences between LOAD and NC demographic subject data, all 
normally distributed values were analyzed using Student’s t test, while non-normally 
distributed data were analyzed using the nonparametric Mann-Whitney U test. All subject 
demographic significance tests were performed in SigmaPlot v.13 (Systat Software, Inc., 
San Jose, CA, USA).
Results
As an initial study to determine differences in site-specific levels of 5-hmC in the HPG of 
LOAD subjects, the epigenome of three LOAD and two NC subjects were compared. No 
significant differences were found between groups in PMI or neurofibrillary tangle (NFT) 
burden in the CA1 using Student’s t test (p < 0.05) (Table 1). The NFT burden in the 
subiculum (Sub) of AD subjects was significantly higher compared to NC (p = 0.02, t-test). 
Although epigenetic landscapes have been suggested to change with increasing age 
(Teschendorff et al. 2013, Issa 2014, Shah et al. 2014), the ages of LOAD and NC subjects 
were not significantly different, theoretically correcting for changes in epigenetic 
mechanisms associated with age. While there was a clear difference in the median Braak 
stage scores and MMSE between the LOAD and NC groups, the small number of subjects 
prevented a significant p value (p=0.2, Mann-Whitney U).
To analyze 5-hmC across the genome of LOAD subjects, Zymo Research Corporation’s 
RRHP sequencing technique was utilized. By optimizing the relationship between specific 
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restriction endonucleases and cut sites, 5-hmC can be mapped throughout the genome at the 
single base resolution. RRHP sequencing identified more than 2 million potential sites of 5-
hmC modification at CCGG sequences throughout the genome from 3 LOAD and 2 NC 
subjects and read counts of 5-hmC at each site were determined by ZRC (Online Resource 
File 1). Aligned BAM files were downloaded from ZRC and analyzed using a sliding 
window approach to analyze count data across the genome. Due to the complexity of the 
data set, (i.e. genome wide counts of 5-hmC, likely over-dispersion within the data sets, and 
biological replicates for each group), a negative binomial distribution was applied.
The window size was set to 200 bp with a slide of 20 bp. The diffReps program uses a 
default initial statistical cutoff of p < 1e−04, which included 3.29e08 windows in our analysis. 
To correct for multiple comparisons, FDR adjusted values were calculated, resulting in 
1.65e06 windows, which were annotated to the hg19 genome. The statistical cutoff 
predefined in diffReps for the negative binomial test has an estimated FDR of 0.2%, 
however, due to the small sample size in our analysis, we chose a conservative adjusted 
significance p value (p ≤ 1e−04) cutoff which included 43,112 windows (Online Resource 
File 2). Annotation of windows included Ensembl gene and transcript IDs, where single 
windows mapped to several splice variants for a single gene. After removing duplicated 
windows annotated to multiple transcript IDs for a single gene, 15,158 unique windows or 
differentially hydroxymethylated regions (DhmRs) remained. These regions were sorted into 
increased and decreased levels of 5-hmC in LOAD vs NC subjects (Figure 1). The majority 
of these DhmRs show increased levels of 5-hmC in the AD genome, 64% overall, mainly 
confined to promoter and genebody (including intron and exon regions) genomic regions. 
This overall increase in 5-hmC in AD in intragenic regions is consistent with previously 
reported genome wide studies of 5-mC/5-hmC in AD (Bernstein et al. 2016, Zhao et al. 
2017).
Epigenetic modifications to cytosine are believed to be a mechanism for gene activation and 
regulation (Breiling & Lyko 2015). To analyze the 5-hmC modification sites relevant to AD 
gene expression changes, the DhmRs were sorted to only include sites within genes with 
altered gene expression in sporadic AD in the hippocampus according to a published 
microarray (Blalock et al. 2004). This narrowed our list to 329 genes with altered expression 
as well as altered levels of 5-hmC (Table 2).
To determine biologically relevant pathways in AD containing the 329 genes from our 
analysis, Reactome FI was used to create a gene network of likely interactions. The curated 
network, containing 322 target genes, was clustered into six modules and pathway 
enrichment analysis was performed on each module, excluding linker genes included in the 
network build by RFI (Figure 2). Only pathways with an adjusted FDR (p < 0.05) were 
retained. To simplify results, significantly enriched pathways within the modules relevant to 
AD and neurodegeneration are discussed below (for complete list of significantly enriched 
pathways and genes identified, see Online Resource Files 3a-b).
Enriched pathways highlighted in the current study for the signaling module include calcium 
signaling, Wnt signaling, synapse signaling, and long-term depression. In the energy 
metabolism module, the TCA cycle and electron transport, several neurodegenerative 
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diseases, cGMP-PKG signaling, and axon guidance mechanisms show significant alterations 
in 5-hmC levels. The cell cycle module included significant enriched pathways related to 
BER, transcription pathways, notch signaling, and endocytosis. For the gene expression 
module, RNA polymerase and mitochondrial transcription, as well as processing of pre-
mRNA pathways were significantly enriched. Additionally, protein degradation pathways, 
like ubiquitin mediated proteolysis and degradation of cell cycle proteins, as well as cell 
structure and stabilization pathways, like focal adhesion, extracellular matrix organization, 
actin cytoskeleton regulation, and NCAM signaling for neurite out-growth, show significant 
alterations in 5-hmC (Figure 2b).
Significantly enriched pathways with similar genes, including signaling pathways of four 
types of neurons (cholinergic, dopaminergic, glutamatergic, and serotonergic neurons) and 
three neurodegenerative diseases (Huntington’s disease, Parkinson’s disease, and 
Alzheimer’s disease) were combined and the largest adjusted p value for the combined 
pathways was reported (denoted with ╪ in Figure 2). For specific genes within each 
enriched pathway, please refer to Online Resource File 3b.
Discussion
While there have been great advances in our understanding of AD genes and pathways that 
lead to neuron dysfunction and degeneration, the mechanism of how sporadic AD begins 
still remains unanswered. To date, no cure or treatment plan has shown success in halting or 
slowing the aggressive and destructive progression of this disease. In the absence of genetic 
mutations to account for loss of function in the sporadic form of AD, environmental factors 
may hold the key to causal mechanisms. Epigenetic modifications in the disease could 
potentially be causal to the shift in gene transcription evident in AD progression.
Epigenetic modifications to cytosine are known to play a role in the regulation of 
transcription although the exact mechanism is not well understood. To filter our list of genes 
with significantly altered 5-hmC levels in the hippocampus of sporadic AD subjects, a 
previously published microarray of differentially expressed genes in mild, moderate, and 
severe cases of sporadic AD compared to age-matched NC subjects was used (Blalock et al. 
2004). The resulting list of 329 genes with AD related transcriptional and epigenetic 
alterations was then subjected to network analysis software to find meaningful biologically 
relevant pathways related to AD and neurodegeneration. Reactome FI (RFI), a Cytoscape 
(Shannon et al. 2003) plugin app, combines gene ontology and biological pathways curated 
from online sources including CellMap (Krogan et al. 2015), Reactome (Milacic et al. 2012, 
Croft et al. 2014), KEGG pathways (Kanehisa & Goto 2000, Kanehisa et al. 2016, Kanehisa 
et al. 2017), NCI PID (Schaefer et al. 2009), Panther (Thomas et al. 2003), and BioCarta 
(Nishimura 2004). From our list of target genes, the curated network, including 322 genes, 
was clustered into modules containing genes related to signaling, energy metabolism, cell 
function processes, gene expression, protein degradation, and cell structure and stabilization 
(Figure 2). The relevance of significantly enriched pathways within each module to AD, as 
well as specific genes within them, are discussed below.
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Several genes identified within significantly enriched pathways in the signaling and cell 
cycle modules of our network gene ontology analysis have also been implicated as genes 
that play a role in the pathophysiology of sporadic AD, including complement receptor 1 
(CR1), bridging integrator 1 (BIN1), and clusterin (CLU). These genes have continuously 
appeared as target genes in genome-wide association studies of AD subjects (Lambert et al. 
2009, Seshadri et al. 2010) as well as genome-wide methylation mapping studies (De Jager 
et al. 2014, Yu et al. 2015, Watson et al. 2016) for their roles in endocytosis, immune 
function, lipid processing, and clearance mechanisms (Tan et al. 2013). While not as 
strongly associated with AD genome-wide associate studies as the aforementioned genes, 
DLGAP1, a postsynaptic density regulator, is a suggested gene with AD relevant SNPs and 
likely plays a role in sporadic AD (Bertram et al. 2008).
Deregulation of cellular signaling, particularly at the synapse, is a common feature in 
neurodegeneration and neuropsychological disorders. Our network analysis showed 
numerous pathways within the signaling module with altered regions of 5-hmC and 
expression in the hippocampus. Genes encoding for G proteins (eg. GNAO1, GNA14, 
GNAL, GNAS, GNAZ, GNB1), as well as phospholipase C (eg. PLCB1, PLCE1, PLCG2), 
and adenylate cyclase (eg. ADCY2, ADCY3, ADCY7, ADCY9) proteins within synapse 
and calcium signaling cascades regulate gene expression, exocytosis, and long-term 
depression within neurons according to curated KEGG pathways. Synaptic signaling 
pathways specific to cholinergic, serotonergic, dopaminergic, and glutamatergic neurons 
show altered levels of 5-hmC in our study and have been gene targets in neurodegeneration 
and neuropsychological disorder studies. Protein levels of SHANK2 (SH3 and Multiple 
Ankyrin Repeat Domains 2) were elevated at the postsynaptic density of AD subjects where 
glutamate receptor dysfunction leads to destruction of the Shank- postsynaptic platform 
likely contributing to synapse loss in AD (Gong et al. 2009). Epigenetic dysregulation of 
HTR2A, 5-Hydroxytryptamine Receptor 2A, occurs in brain regions of early onset 
schizophrenia and bipolar disorder patients (Abdolmaleky et al. 2011), and loss of HTR2A 
receptors in AD brain correlates to rate of cognitive decline (Lai et al. 2005). Genes within 
these signaling pathways also regulate sodium (GRIA3), calcium (CACNA1), and potassium 
(eg. KCNJ14, KCNQ2) ion channels, including KCNA6, a potassium channel gene thought 
to play a role in insulin secretion and neurotransmitter release (Etcheberrigaray et al. 1994). 
KCNA6 was also identified as a “hub gene” in a recent 5-hmC mapping study of prefrontal 
cortex AD brain, associating hydroxymethylation and neuropathological burden (Zhao et al. 
2017).
Wnt signaling plays a critical role in many cellular processes including adhesion, survival, 
proliferation, differentiation, and apoptotic pathways (Clevers & Nusse 2012, Nusse 2012). 
Many genes within Wnt signaling pathways identified in our analysis have been implicated 
in AD. Genetic variations in LRP6 (LDL Receptor Related Protein 6) have been shown to 
lead to AD progression (De Ferrari et al. 2007). One of the susceptibility genes identified for 
late onset AD, CLU, regulates β-amyloid toxicity in the non-canonical Wnt/PCP pathway 
known to contribute to tau phosphorylation and cognitive decline (Killick et al. 2014). A 
recent study of an APP/PS1 transgenic mouse model of AD showed downregulation of 
WNT7B, involved in synapse organization according to gene ontology analysis (Orre et al. 
2014a), as well as altered expression of WNT7B in hippocampal tissue of AD subjects 
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(Riise et al. 2015). Several studies show that alterations in Wnt signaling pathways are 
involved in the regulation of synaptic development and likely play a role in the progression 
of AD (Vargas et al. 2014).
Deregulation of energy metabolism processing and mitochondrial function is a major 
hallmark across neurodegenerative diseases, including Huntington’s disease, Parkinson’s 
disease, and AD (Godoy et al. 2014). Key mechanisms in the production of energy needed 
for healthy cellular function include the TCA cycle, electron transport chain processes, and 
the regulation of insulin signaling processes. Genes involved in regulating the TCA cycle 
(eg. OGDH) show decreased expression in AD brain and in AD mouse models (Bubber et al. 
2005, Ciavardelli et al. 2010). Genes regulating mitochondrial complexes I-V, i.e. the 
electron transport chain, including NADH dehydrogenases (eg. NDUFA3, NDUFA10, 
NDUFB3) ATP synthase (eg. ATP5J, ATP5B) succinate dehydrogenase (SDHD), and 
ubiquinol-cytochrome c reductase (UQCRC2), also show transcription alterations across 
neurological dysfunction disorders (Liang et al. 2008, Ferreira et al. 2010, Zhang et al. 
2015). Genes relevant to insulin processing mechanisms (eg INSR, IRS2) necessary for 
learning and synaptic plasticity (Horwood et al. 2006) also modulate neurotransmission in 
glutamate receptors and recruitment of GABA receptors to postsynaptic sites (Wan et al. 
1997). While there is no definitive link between diabetes and AD, overlapping pathways 
regulated by insulin suggest a possible role in altered energy metabolism and 
neurodegeneration (Akter et al. 2011). The deregulation of energy metabolism pathways 
plays key roles in neuron stabilization and axon guidance and development. Plexins and 
semaphorins, a family of axon guidance cues, have also been shown to facilitate downstream 
pathways leading to phosphorylation of tau, ultimately causing microtubule destabilization 
(Uchida et al. 2005). In a gliomal brain cancer model, PLXNB2 was shown to be an 
activator of Rho-GTPase pathways, potentially causing downstream affects in dendrite 
formation and maintenance (Le et al. 2015), while genes in the SEMA3 family of proteins 
(eg. SEMA3B, SEMA3F) have been shown to facilitate attractive and repulsive axon 
guidance mechanisms (Falk et al. 2005). Axon initial segments require ANK3 (ankryin 3 or 
ankryin G), a scaffolding protein, to form and are disrupted by Aβ plaques in a mouse model 
of AD, reducing the length of axon segments and overall neuron excitability (Marin et al. 
2016).
Alterations in cell function pathways are key features of many diseases, including cancer 
and neurodegeneration (Klein & Ackerman 2003, Maddika et al. 2007). These pathways 
include base excision repair mechanisms, endocytosis pathways, as well as NOTCH 
signaling, transcription and gene expression. Oxidative damage to DNA is an established 
feature of neurodegeneration throughout the progression of AD (Markesbery 1997, Lovell & 
Markesbery 2007b, Lovell & Markesbery 2007a), and genes involved in base excision repair 
(BER) mechanisms appear to play a role in epigenetic modifications to cytosine (Weber et 
al. 2016). In our analysis, BER genes (OGG1, TDG, and UNG) show altered levels of 5-
hmC in the hippocampus and show decreased expression throughout the progression of AD 
(Weissman et al. 2007, Lovell et al. 2011). Genes within endocytosis mechanisms, including 
FGFR3 and TGFB1, show altered levels of expression in AD mouse models (Salins et al. 
2008, Orre et al. 2014b), and TGFB1 levels were increased in CSF of probable AD patients 
(Rota et al. 2006). BIN1, a recently discovered risk factor gene for sporadic AD, not only 
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regulates endocytosis and other cell function mechanisms, but also may aid in tau pathology 
development in AD (Tan et al. 2013). Signaling cascades involving the NOTCH family of 
proteins, regulators of presenilin pathways, and genes with NOTCH signaling pathways, 
likely play significant roles in amyloid production and plaque formation. AD associated 
SNPs in NOTCH4 were discovered in a northern Israeli population study, a population with 
an abnormally high prevalence of sporadic AD (Sherva et al. 2011). NCOR2, a 
transcriptional regulatory hub gene, affects memory formation in AD brain (Acquaah-
Mensah & Taylor 2016), while TCF3 showed increased expression in the hippocampus of 
AD subjects, along with several integral Wnt signaling genes (Riise et al. 2015). 
Dysfunction in transcriptional regulatory mechanisms, including regulator genes CREBBP 
and NR2F6, lead to neuronal apoptosis (Rouaux et al. 2003) and deficits in early memory 
and learning in an AD mouse model (Kummer et al. 2014). Gene expression mechanisms 
involving RNA polymerase also regulate splicing pathways (eg. PTBP1, PRPF8, CDC5L), 
and when deregulated, these genes can alter neuron differentiation pathways, repress pre-
mRNA splicing mechanisms, and deregulate cell proliferation (Makeyev et al. 2007, 
Kurtovic-Kozaric et al. 2015). CDK7, a regulator of cell cycle pathways and a member of a 
transcription factor complex that activates RNA Polymerase II, is upregulated in the 
hippocampus of AD subjects (Zhu et al. 2000).
Protein degradation and clearance mechanisms are essential to healthy cellular function, 
while the disruption of proper clearance and degradation pathways, like the ubiquitin-
proteasome system, lead to the accumulation of intracellular aggregate-prone proteins 
ultimately causing cell loss and neurodegeneration (Popovic et al. 2014, Zheng et al. 2016). 
Not only in degradation pathways, but the ubiquitination of proteins is also essential for 
endocytosis, trafficking, signaling, and DNA repair mechanisms (Grabbe et al. 2011, 
Kulathu & Komander 2012, Rieser et al. 2013). PSMA1, a proteasome protein, showed 
increased levels in the serum of mild cognitive impairment and probable AD vs cognitively 
normal subjects (Kang et al. 2016). Genes that regulate ubiquitination mechanisms are also 
involved in Wnt-signaling including BTRC and FZR1. BTRC regulates phosphorylated β-
catenin (Hart et al. 1999), a Wnt-pathway gene involved in regulating gene transcription, 
where increased levels of phosphorylated β-catenin lead to proteasome dysfunction 
(Ghanevati & Miller 2005). While ubiquitin mediated protein degradation appears to play a 
significant role in the progression of neurodegeneration and in several pathways critical to 
healthy cellular function, the exact mechanism is not well understood (Zheng et al. 2016).
The maintenance and regulation of pathways involved in cell structure and stabilization play 
important roles in neuronal function and healthy synapse formation. Focal adhesions are 
structures that form between membrane receptors and the actin cytoskeleton, signaling 
molecules that result in the reorganization of the actin cytoskeleton, and can regulate gene 
expression via growth factor mediated signaling (Iskratsch et al. 2014). Focal adhesion 
genes, including integrin receptors (eg. ITGB4, ITGB5, ITGB8) and collagen proteins (eg. 
COL4A1, COL4A3, COL6A2) regulate extracellular matrix organization mechanisms and 
lie upstream of actin polymerization and Wnt-signaling pathways. The proper regulation of 
actin is essential for healthy cell homeostasis. The phosphorylation of LIM domain kinase 
(eg. LIMK2) leads to phosphorylation of cofilin, an actin severing protein, rendering it 
inactive, and allowing for actin cytoskeleton reorganization (Sumi et al. 1999). Cofilin is 
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activated by the dephosphorylation of slingshot, which is activated by the phosphorylation 
by p21 activated protein kinase 4 (PAK4) (Soosairajah et al. 2005). Activation of cofilin 
leads to actin filament turnover, while the inactivation of cofilin leads to actin cytoskeleton 
reorganization. Current studies show that cofilin is deregulated in AD (Barone et al. 2014). 
NRXN1, a presynaptic ligand linked to autism, is thought to be a component of the synaptic 
regulatory pathway, where dysregulation of neurexins and neuroligins can lead to alterations 
in dendritic spine morphology (Sudhof 2008, Penzes et al. 2011).
The precise role of epigenetic modifications to cytosine in neurodegeneration remains to be 
determined, however it is clear that levels of 5-mC and 5-hmC are altered in AD and other 
neurodegenerative diseases on global and loci-specific scales (Sanchez-Mut et al. 2016, 
Ellison et al. 2017). While this initial study of loci-specific levels of 5-hmC in the 
hippocampus of LOAD subjects compared to NC was limited by sample size, to obtain a 
better understanding of changes to epigenetic marks in AD, larger sample sizes should be 
evaluated. Advances in loci- specific techniques to study whole epigenomes have increased 
greatly in the past several years, however the cost of this new technology is high, limiting the 
number of subjects per analysis. Although samples sizes were small, two previously 
published studies of differentially hydroxymethylated regions of the AD genome in 
prefrontal cortex tissue specimens (Bernstein et al. 2016, Zhao et al. 2017) showed several 
overlapping genes with altered hydroxymethylation in our gene list. One gene common to all 
three genome-wide 5-hmC studies in AD brain, myelin transcription factor 1-like (MYT1L), 
was used to produce induced neuronal cells and has been described as a neuronal fate 
inducing factor (Vierbuchen et al. 2010), however the function of MYT1L in AD brain has 
yet to be determined. The overlap of genes within these studies, despite variation in brain 
regions analyzed (hippocampus and prefrontal cortex) and discrepancy in sequencing 
techniques (5-hmC single base resolution mapping and 5-hmC enrichment analysis), 
strengthens the validity of this initial study of genes within biologically relevant pathways 
that show alterations in 5-hmC levels as well as alteration in gene expression in the 
hippocampus of LOAD subjects.
It should also be noted that genes with DhmRs in this analysis represent a mixture of cell 
types, including neuronal and glial cells. While 5-hmC levels are cell-type specific (Nestor 
et al. 2012), the current study lacks the specificity to identify whether 5-hmC alterations in 
AD are representative of glia, neurons, or a combination of both. Significant changes to 
levels of 5-mC and 5-hmC have been shown in both neuronal and glial cells in previous AD 
studies (Mastroeni et al. 2010, Chouliaras et al. 2013), however further research is needed to 
clarify the specific roles both neuronal and glial cytosine modifications play in AD.
Finally, the gender distribution of the subjects, including one male subject in the LOAD 
subject pool, should be considered. Exclusion of this subject, resulting in two female LOAD 
and two female NC subjects, gave 231 of the original 329 genes using the conservative FDR 
cutoff (p ≤ 1e−04). Enrichment analysis using RFI gave similar results, including significant 
enrichment (FDR, p < 0.05) in pathways involved in signaling, energy metabolism, cell 
function, gene expression, degradation, and cell structure and stabilization (Online Resource 
File 4). However, in future studies, similar distributions in gender should be analyzed to 
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prevent gender bias and achieve a more complete picture of how epigenetic modifications 
affect gene expression in AD.
Conclusion
It remains unclear if epigenetic modifications are upstream or downstream of 
neurodegeneration associated with the progression of AD, but it is highly likely that 
epigenetics play a role in the disease. Whether these changes instigate pathology or are an 
attempt to reestablish homeostasis still remains to be determined. To analyze the exact role, 
changes in early stages of AD may give clearer insights into the mechanism of dysfunction 
rather than levels of markers in the final stage of the disease. However, suggested pathways 
that seem to be deregulated in late stage AD, both changes to transcriptional states as well as 
epigenetic modifications, could give insight into mechanisms that are altered in AD, 
providing possible therapeutic targets to study earlier in disease progression.
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Figure 1. 5-hmC distribution
Overall distribution of 15,158 DhmRs in intragenic and intergenic genomic locations. 
Intragenic locations, including promoter and genebody (exons and introns) regions, show the 
majority of DhmRs. Distribution of genomic regions for increased (white) and decreased 
(gray) DhmRs passing FDR cutoff (p ≤ 1e−04) are labeled.
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Figure 2. Functional Interactive network
Using Reactome FI, a gene network was created using 322 genes with significant alterations 
in 5-hmC. Linker genes are shown as diamonds, while the 322 target genes are depicted with 
circles (a). The network was clustered into six modules and pathway enrichment analysis 
was performed. To correct for multiple comparisons, false discovery rate p values were 
calculated (p < 0.05). Significantly enriched pathways within each module are listed with p 
values (b). Like terms were combined (Neurodegenerative disease: Huntington disease, 
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Parkinson’s disease, and AD; Synapse signaling: dopaminergic, serotoninergic, cholinergic, 
and glutamatergic synapse signaling) and the least significant FDR was reported (╪).
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Table 1
Demographic data of LOAD and NC subjects.
Demographics NC LOAD
Gender 2F 2F/1M
Age (y) 84.5 ± 0.7 85.3 ± 4.0
PMI (h) 2.5 3.0 ± 0.7
MMSE 29 5
Braak Stage 0 VI
NFT (CA1) 0 66.5 ± 38.9
NFT (Sub) 0 109.5 ± 30.6*
Age, postmortem interval (PMI), Braak stage score, MMSE and neurofibrillary tangle (NFT) burden were compared. NFT burden values were 
determined for CA1 and subiculum (Sub) HPG regions. Statistical significance was determined using Student’s t-test or Mann-Whitney U (MWU) 
analysis
*p < 0.05.
Age, PMI, and NFT counts are given as mean ± SD, while MMSE and Braak Stage are median scores for each subject group.
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Table 2
Modules and genes from Reactome FI network analysis.
RFI Network Module Gene List
Module 0: Signaling ABL1, ABLIM1, ACTR2, ADCY2, APBA2, ARHGEF10, ARHGEF16, C4B, CACNA1A, CDH10, CDH13, 
CDH4, CLIC2, CNTNAP2, CR1, CSK, DGKG, DIAPH2, DLGAP1, ENAH, F2R, GAK, GNA12, GNA14, 
GNAL, GNAO1, GNAS, GNAZ, GPR4, GRIA3, GRIN2A, GRM6, HTR2A, IQGAP1, ITPK1, JPH3, 
KCNA6, KCNAB1, KCNAB2, KCNJ14, LRP1B, LRP6, MADCAM1, MAP2K3, MYO1C, MYO1F, 
MYO9B, NFATC1, NMB, PDE4C, PLCB1, PLCE1, PLCG2, PLCL2, PRKAR1B, PRKAR2B, PTN, 
RAB22A, RALBP1, RALGDS, RAMP1, RANBP3, RTN1, SH3BP2, SHANK2, STK11, TRPV1, ULK2, 
WNT7B
Module 1: Energy Metabolism AATK, ACAT1, ANK3, AP2B1, APC2, ATP1A2, ATP2B2, ATP5B, ATP5J, ATP5J2, BAIAP3, BGN, 
CADPS, CAP2, CEPT1, CHST3, CSNK1E, EDAR, EHD1, ELF2, EPS15, FEZ2, FOLH1, FRAT1, FYCO1, 
G6PD, GHITM, GOSR2, GPM6B, HADHA, INSR, IRS2, ITPR1, KIF13B, L1CAM, MGA, MKNK2, 
NDUFA10, NDUFA3, NDUFB3, NME4, OGDH, PLXNA1, PLXNB2, POLRMT, QARS, RPS6KA1, 
SCAMP3, SDHD, SEMA3B, SEMA3F, SLC12A7, SLC1A7, SLC25A12, SLC25A6, SLC7A5, STK10, 
TCEAL1, TPD52, TUBG2, TYK2, UQCRC2, USP3, UST, WFS1, ZNF142
Module 2: Cell Function AK5, AKAP12, AMPD3, BIN1, BRD4, CAMKK2, CCND3, CEBPD, CHD2, CLU, CPT1B, CREBBP, 
DAPK2, DAPK3, DRAP1, FADS1, FGFR3, GDF1, HBA1, IL6R, IRF7, JUND, KCNN3, KLF1, LDLR, 
LPIN1, LTBP2, MAGED1, MAPRE3, MTF1, NCOR2, NFIC, NOTCH4, NPAS2, NPAS3, NR2F6, OGG1, 
OSBPL10, PKNOX2, PPP1R15A, RBL1, RREB1, SH3GLB2, SPIB, SREBF1, SREBF2, SSBP1, STK24, 
TCF3, TDG, TGFB1, THRA, TRIM26, UNG, WFDC1
Module 3: Gene Expression BANP, BCL7A, CCNA1, CDC5L, CDK7, COMT, CPSF1, CTBP1, CTBP2, DDX27, DGCR6, FSTL1, GPI, 
H2AFX, HDAC4, LMNA, LZTS1, MBD3, MPST, MTA1, MUC3A, MYT1L, NELL1, PAX6, PML, PRPF8, 
PTBP1, PTRF, REC8, SIRT6, SIRT7, SLC19A1, SMARCA2, SNRPD2, STAG2, SYN2, TCF7, TFAP2A, 
TLE3, VARS2
Module 4: Protein degradation AGPAT2, AMFR, ARIH2, BTRC, CDC34, CUL5, ENSA, FBXL2, FZR1, GLI2, GMEB2, MGLL, NME3, 
ODC1, PER1, PLOD3, PPP2R2B, PRDX3, PRL, PRPF4B, PSMA1, PSMD14, RNF11, SPTLC2, TIMM44, 
TTC3, UBE3B, WWOX, ZIC1
Module 5: Cell Structure and 
Stabilization
ACTN1, COL21A1, COL4A1, COL4A3, COL6A2, DAG1, DMD, FLNA, FLNC, GPC5, GPR56, ITGB4, 
ITGB5, ITGB8, LIMK2, LRP8, MAFF, MAFG, MAP2K7, MAP3K11, NDST1, NRXN1, PACSIN2, PAK4, 
RGS12, SNTA1, SORBS1, TNXB, VWF
Genes used to build RFI network included 322 out of the 329 genes with altered 5-hmC levels according to our analysis, as well as differentially 
expressed in the HPG of AD subjects (Blalock et al, 2004). Pathway enrichment analysis was performed on each module containing the genes 
above.
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